Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors
17 12월 2022 - 6:01AM
Business Wire
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic
solutions company with a focus in lung disease, today announced the
appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company’s
Board of Directors (Board) and Audit Committee of the Board
effective January 3, 2023. Mr. Kennedy brings to Biodesix more than
20 years of broad operating, corporate finance, company creation
and investment experience with a specific focus in the healthcare
industry.
“We are delighted to welcome Lair to Biodesix’s Board of
Directors,” said Scott Hutton, Chief Executive Officer of Biodesix.
“He brings a wealth of business experience with a strong background
in healthcare and diagnostics. We look forward to working with Lair
and believe his guidance and input will strengthen our board as we
advance our mission and goal of becoming a leading data-driven
diagnostic solutions company, working to unite biopharma,
physicians, and patients to transform the standard of care and
improve lung cancer outcomes with personalized diagnostics.”
Mr. Kennedy currently serves as the Managing Partner and Chief
Executive Officer of Westwood Management, a private investment and
wealth management firm directing a diverse investment portfolio
across a range of alternative and traditional asset classes. Prior
to his role at Westwood Management, Mr. Kennedy was the co-founder
of Health Carousel, a talent management company with a leading
portfolio of healthcare staffing and workforce solution businesses.
Mr. Kennedy currently serves on the boards of directors of
Healthcare for Kids, HC Locum, Revolution 4.0, and Health Carousel.
Mr. Kennedy has received a Master of Business Administration from
Duke University’s Fuqua School of Business and a Bachelor of Arts
from Colgate University.
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company
with a focus in lung disease. The Company develops diagnostic tests
addressing important clinical questions by combining multi-omics
through the power of artificial intelligence. Biodesix offers five
Medicare-covered tests for patients with lung diseases. The blood
based Nodify Lung® nodule risk assessment testing strategy,
consisting of the NodifyXL2® and the Nodify CDT® tests, evaluates
the risk of malignancy in pulmonary nodules, enabling physicians to
better triage patients to the most appropriate course of action.
The blood based IQLung™ strategy for lung cancer patients
integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS™
test and the VeriStrat® test to support treatment decisions across
all stages of lung cancer with results in an average of 36-72
hours, expediting time to treatment. Biodesix also leverages the
proprietary and advanced Diagnostic Cortex® AI (Artificial
Intelligence) platform, to collaborate with many of the world’s
leading biotechnology and pharmaceutical companies to solve complex
diagnostic challenges in lung disease. For more information about
Biodesix, visit biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release other
than statements of historical fact, are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of the COVID-19 pandemic on Biodesix and its
operations, its possible or assumed future results of operations,
including descriptions of its revenues, profitability, outlook, and
overall business strategy. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. The Company's ability to continue as a
going concern could cause actual results to differ materially from
those contemplated in this press release and additionally, other
factors that could cause actual results to differ materially from
those contemplated in this press release can be found in the Risk
Factors section of Biodesix’s most recent annual report on Form
10-K, filed March 14, 2022 or subsequent quarterly reports on Form
10-Q during 2022, if applicable. Biodesix undertakes no obligation
to revise or publicly release the results of any revision to such
forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221216005452/en/
Media: Robin Harper Cowie robin.cowie@biodesix.com (720)
509-8841
Investors: Chris Brinzey chris.brinzey@westwicke.com
(339) 970-2843
Biodesix (NASDAQ:BDSX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Biodesix (NASDAQ:BDSX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024